neovii
news & events
03/11/2021

Jürgen Pohle

neovii
03/11/2021

In his role, he leads the global commercial organization for further growth and development of products. Mr. Pohle joined Neovii in 2016 bringing over 25 years of experience in the pharmaceutical industry. Prior to joining Neovii, he held senior leadership positions at GSK, Novartis, and Bayer HealthCare. Mr. Pohle holds a law degree from the University of Cologne, Germany.

Related Articles

Learn more about Neovii world

NEOVII Partners with Tel Aviv University to Develop Novel COVID-19 Vaccine

The epitope-based vaccine will target the most vulnerable part of the viral spike protein. Rapperswil, Switzerland and Tel Aviv, Israel, 12th May 2020 – Ramot, Tel Aviv University’s technology transfer company, and Neovii, a Swiss-based biopharmaceutical company and a member of Israel-based Neopharm Group, announced today that they have signed a research and license agreement to develop a novel and potentially […]

13. 05. 2020

Neovii & Mundipharma Confirm In-licensing Agreement

Neovii & Mundipharma Confirm In-licensing Agreement for the Development and Promotion of Grafalon® in China and Japan for Solid Organ & Stem Cell Transplant Neovii and Mundipharma have entered into an agreement giving Mundipharma the rights to develop and distribute its polyclonal antibody immunosuppressant Grafalon®, in China and Japan from end October 2018. Grafalon® is currently approved for prevention of […]

31. 05. 2019

Neovii Pharmaceuticals AG announces new CEO

Rapperswil, Switzerland, September 15, 2017 – Alexandre Sudarskis, Chief Executive Officer (CEO) of Neovii Pharmaceuticals will step down as CEO having reached retirement age. Neovii Pharmaceuticals appointed Juergen Pohle, Chief Commercial Officer, as CEO and Managing Director of Neovii as of January 1, 2018. CEO since June 2014, Alexandre Sudarskis established Neovii Pharmaceuticals’ headquarters in Switzerland […]

15. 09. 2017